Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNTH NASDAQ:ERAS NASDAQ:TNGX NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$82.49+0.7%$86.74$16.64▼$96.50$4.48B1.18967,641 shs2.48 million shsERASErasca$13.67-2.2%$13.93$1.21▼$24.28$4.35B0.734.76 million shs9.64 million shsTNGXTango Therapeutics$27.97-13.4%$24.30$4.60▼$34.39$4.67B1.194.61 million shs12.09 million shsWVEWAVE Life Sciences$6.16+3.5%$6.66$5.02▼$21.73$1.14B-1.333.08 million shs5.10 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics+3.82%+7.16%-2.05%+2.36%+374.17%ERASErasca+4.48%+4.56%+36.12%-8.39%+924.18%TNGXTango Therapeutics+0.40%+12.59%+56.52%+67.13%+572.71%WVEWAVE Life Sciences+3.66%+5.12%-7.03%-50.91%-9.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$82.49+0.7%$86.74$16.64▼$96.50$4.48B1.18967,641 shs2.48 million shsERASErasca$13.67-2.2%$13.93$1.21▼$24.28$4.35B0.734.76 million shs9.64 million shsTNGXTango Therapeutics$27.97-13.4%$24.30$4.60▼$34.39$4.67B1.194.61 million shs12.09 million shsWVEWAVE Life Sciences$6.16+3.5%$6.66$5.02▼$21.73$1.14B-1.333.08 million shs5.10 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics+3.82%+7.16%-2.05%+2.36%+374.17%ERASErasca+4.48%+4.56%+36.12%-8.39%+924.18%TNGXTango Therapeutics+0.40%+12.59%+56.52%+67.13%+572.71%WVEWAVE Life Sciences+3.66%+5.12%-7.03%-50.91%-9.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNTHDianthus Therapeutics 2.93Moderate Buy$117.8242.83% UpsideERASErasca 2.60Moderate Buy$20.1147.12% UpsideTNGXTango Therapeutics 2.71Moderate Buy$38.4237.35% UpsideWVEWAVE Life Sciences 2.87Moderate Buy$26.41328.76% UpsideCurrent Analyst Ratings BreakdownLatest WVE, ERAS, TNGX, and DNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026TNGXTango Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/11/2026ERASErasca Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/11/2026WVEWAVE Life Sciences New Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.006/11/2026WVEWAVE Life Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/10/2026DNTHDianthus Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/10/2026DNTHDianthus Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/10/2026DNTHDianthus Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy6/10/2026DNTHDianthus Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/9/2026TNGXTango Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $66.006/9/2026TNGXTango Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $42.006/8/2026TNGXTango Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$36.00(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNTHDianthus Therapeutics$2.04M2,210.65N/AN/A$11.41 per share7.23ERASErascaN/AN/AN/AN/A$1.05 per shareN/ATNGXTango Therapeutics$56.99M70.99N/AN/A$2.57 per share10.88WVEWAVE Life Sciences$42.73M27.74N/AN/A$3.10 per share1.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNTHDianthus Therapeutics-$162.34M-$4.13N/AN/AN/A-12,998.50%-27.30%-25.91%8/6/2026 (Estimated)ERASErasca-$124.55M-$0.93N/AN/AN/AN/A-35.31%-29.49%8/11/2026 (Estimated)TNGXTango Therapeutics-$101.59M-$0.83N/AN/AN/A-151.15%-41.54%-33.44%8/4/2026 (Estimated)WVEWAVE Life Sciences-$204.38M-$1.06N/AN/AN/A-255.70%-56.76%-42.80%7/30/2026 (Estimated)Latest WVE, ERAS, TNGX, and DNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026TNGXTango Therapeutics-$0.32-$0.32N/A-$0.32$0.58 millionN/A5/11/2026Q1 2026ERASErasca-$0.1150-$0.60-$0.4850-$0.60N/AN/A5/5/2026Q1 2026DNTHDianthus Therapeutics-$1.0719-$0.85+$0.2219-$0.85$0.40 million$0.46 million4/29/2026Q1 2026WVEWAVE Life Sciences-$0.34-$0.13+$0.21-$0.13$8.45 million$38.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDNTHDianthus TherapeuticsN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNTHDianthus TherapeuticsN/A29.2529.25ERASErascaN/A9.529.52TNGXTango TherapeuticsN/A27.3827.38WVEWAVE Life SciencesN/A11.2611.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNTHDianthus Therapeutics47.53%ERASErasca67.78%TNGXTango Therapeutics78.99%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipDNTHDianthus Therapeutics3.02%ERASErasca14.20%TNGXTango Therapeutics6.50%WVEWAVE Life Sciences24.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNTHDianthus Therapeutics8054.67 million53.02 millionOptionableERASErasca120310.99 million266.83 millionOptionableTNGXTango Therapeutics90144.65 million135.25 millionOptionableWVEWAVE Life Sciences240192.40 million145.65 millionOptionableWVE, ERAS, TNGX, and DNTH HeadlinesRecent News About These CompaniesWave Life Sciences (WVE) Upgraded to Buy: Here's WhyJune 16 at 1:02 PM | zacks.comIs Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now?June 13, 2026 | insidermonkey.comMizuho Securities Remains a Buy on Wave Life Sciences (WVE)June 13, 2026 | theglobeandmail.comIs Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now?June 13, 2026 | finance.yahoo.comBillionaire Lee Ainslie’s 5 Stocks with Huge Upside PotentialJune 12, 2026 | insidermonkey.comInside Wells Fargo’s Take on Wave Life Sciences Ltd (WVE) StockJune 12, 2026 | insidermonkey.comWave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comWave Life Sciences to Present at Upcoming Investor ConferencesJune 1, 2026 | globenewswire.comThis $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First QuarterMay 31, 2026 | fool.comAnalysts Are Bullish on Top Healthcare Stocks: Wave Life Sciences (WVE), Boston Scientific (BSX)May 29, 2026 | theglobeandmail.comWave Life Sciences Ltd. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their LossesMay 27, 2026 | globenewswire.comShould WVE-006’s RNA-Editing AAT Data Shift the Risk-Reward Calculus for Wave Life Sciences (WVE) Investors?May 25, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), Gossamer Bio (GOSS) and Cullinan Management (CGEM)May 21, 2026 | theglobeandmail.comWhat is HC Wainwright's Forecast for WVE FY2028 Earnings?May 21, 2026 | marketbeat.comWave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD DataMay 20, 2026 | seekingalpha.comWVE stock edges up after positive early data for rare disease drugMay 20, 2026 | msn.comBeam one-ups Wave as both show promise of genetic editing for AATDMay 20, 2026 | biospace.comBWave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1May 19, 2026 | prnewswire.comWave Life Sciences Ltd. (WVE) Shareholder/Analyst Call TranscriptMay 19, 2026 | seekingalpha.comWave Life Sciences Ltd. (WVE) Shareholder/Analyst Call - SlideshowMay 18, 2026 | seekingalpha.comWave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly DosingMay 18, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWVE, ERAS, TNGX, and DNTH Company DescriptionsDianthus Therapeutics NASDAQ:DNTH$82.49 +0.60 (+0.73%) Closing price 04:00 PM EasternExtended Trading$82.44 -0.05 (-0.06%) As of 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Erasca NASDAQ:ERAS$13.67 -0.31 (-2.22%) Closing price 04:00 PM EasternExtended Trading$13.80 +0.14 (+0.99%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Tango Therapeutics NASDAQ:TNGX$27.97 -4.32 (-13.38%) Closing price 04:00 PM EasternExtended Trading$28.04 +0.08 (+0.27%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.WAVE Life Sciences NASDAQ:WVE$6.16 +0.21 (+3.53%) Closing price 04:00 PM EasternExtended Trading$6.15 -0.01 (-0.21%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
